These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28893618)

  • 1. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
    Solomon LA; Batista CR; DeKoter RP
    Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
    Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
    Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
    Yang Y; Shaffer AL; Emre NC; Ceribelli M; Zhang M; Wright G; Xiao W; Powell J; Platig J; Kohlhammer H; Young RM; Zhao H; Yang Y; Xu W; Buggy JJ; Balasubramanian S; Mathews LA; Shinn P; Guha R; Ferrer M; Thomas C; Waldmann TA; Staudt LM
    Cancer Cell; 2012 Jun; 21(6):723-37. PubMed ID: 22698399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
    Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK
    Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
    Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
    Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
    Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
    Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
    Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
    Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel mechanism of lenalidomide activity.
    Fink EC; Ebert BL
    Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.